[PRESS RELEASE] – CHICAGO, May 13, 2026 – Verano Holdings Corp., a leading multistate cannabis company, announced that the company has submitted applications with the U.S. Drug Enforcement Administration (DEA) to register certain state-licensed medical cannabis operations, pursuant to the expedited registration pathway provided by the federal rescheduling of medical marijuana to Schedule III of the Controlled Substances Act.
“Submitting the DEA license applications marks a significant step forward for Verano on our path to becoming a federally legal business,” Verano founder, Chairman and CEO George Archos said. “Verano has embraced a medical and patient-first ethos since day one, and with medical cannabis sales accounting for a majority of our retail business, we look forward to unlocking the full medical, research and commercial potential of cannabis under the new Schedule III designation.”
Verano’s active operations span 13 U.S. states, comprised of 162 Zen Leaf™ and MÜV™ dispensaries and 14 production facilities with more than 1.1 million square feet of cultivation capacity.
